These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
262 related articles for article (PubMed ID: 27252269)
1. Autoantibodies to domain 1 of beta 2 glycoprotein I determined using a novel chemiluminescence immunoassay demonstrate association with thrombosis in patients with antiphospholipid syndrome. Mahler M; Albesa R; Zohoury N; Bertolaccini ML; Ateka-Barrutia O; Rodriguez-Garcia JL; Norman GL; Khamashta M Lupus; 2016 Jul; 25(8):911-6. PubMed ID: 27252269 [TBL] [Abstract][Full Text] [Related]
2. Clinical significance of anti-domain 1 β2-glycoprotein I antibodies in antiphospholipid syndrome. Iwaniec T; Kaczor MP; Celińska-Löwenhoff M; Polański S; Musiał J Thromb Res; 2017 May; 153():90-94. PubMed ID: 28363116 [TBL] [Abstract][Full Text] [Related]
3. Detection of IgG anti-Domain I beta2 Glycoprotein I antibodies by chemiluminescence immunoassay in primary antiphospholipid syndrome. Meneghel L; Ruffatti A; Gavasso S; Tonello M; Mattia E; Spiezia L; Tormene D; Hoxha A; Fedrigo M; Simioni P Clin Chim Acta; 2015 Jun; 446():201-5. PubMed ID: 25935129 [TBL] [Abstract][Full Text] [Related]
4. Role of anti-domain 1-β2 glycoprotein I antibodies in the diagnosis and risk stratification of antiphospholipid syndrome. De Craemer AS; Musial J; Devreese KM J Thromb Haemost; 2016 Sep; 14(9):1779-87. PubMed ID: 27314634 [TBL] [Abstract][Full Text] [Related]
5. Detection of anti-domain I antibodies by chemiluminescence enables the identification of high-risk antiphospholipid syndrome patients: A multicenter multiplatform study. Yin D; Chayoua W; Kelchtermans H; de Groot PG; Moore GW; Gris JC; Zuily S; Musial J; de Laat B; Devreese KMJ J Thromb Haemost; 2020 Feb; 18(2):463-478. PubMed ID: 31749277 [TBL] [Abstract][Full Text] [Related]
7. Anti-β2GPI domain 1 antibodies stratify high risk of thrombosis and late pregnancy morbidity in a large cohort of Chinese patients with antiphospholipid syndrome. Liu T; Gu J; Wan L; Hu Q; Teng J; Liu H; Cheng X; Ye J; Su Y; Sun Y; Chi H; Zhou Z; Jia J; Wang Z; Zhou J; Norman GL; Wang X; Yang C; Shi H Thromb Res; 2020 Jan; 185():142-149. PubMed ID: 31816554 [TBL] [Abstract][Full Text] [Related]
8. Clinical performance of automated chemiluminescent methods for anticardiolipin and anti-β2-glycoprotein I antibodies detection in a large cohort of Chinese patients with antiphospholipid syndrome. Wan LY; Gu JY; Liu TT; Hu QY; Jia JC; Teng JL; Sun Y; Liu HL; Cheng XB; Ye JN; Su YT; Wu XY; Chi HH; Zhou ZC; Wang ZH; Zhou JF; Norman GL; Dai J; Yang CD; Shi H Int J Lab Hematol; 2020 Apr; 42(2):206-213. PubMed ID: 31958215 [TBL] [Abstract][Full Text] [Related]
9. The clinical performance of a chemiluminescent immunoassay in detecting anti-cardiolipin and anti-β2 glycoprotein I antibodies. A comparison with a homemade ELISA method. Meneghel L; Ruffatti A; Gavasso S; Tonello M; Mattia E; Spiezia L; Campello E; Hoxha A; Fedrigo M; Punzi L; Simioni P Clin Chem Lab Med; 2015 Jun; 53(7):1083-9. PubMed ID: 25720075 [TBL] [Abstract][Full Text] [Related]
10. Both IgG and IgM anti-beta2 glycoprotein I antibodies assays are clinically useful to the antiphospholipid syndrome diagnosis. Li R; Daguzan M; Vandermijnsbrugge F; Gyling M; Cantinieaux B Acta Clin Belg; 2014 Dec; 69(6):433-8. PubMed ID: 25103595 [TBL] [Abstract][Full Text] [Related]
11. IgA anticardiolipin and IgA anti-β2 glycoprotein I antibody positivity determined by fluorescence enzyme immunoassay in primary antiphospholipid syndrome. Mattia E; Ruffatti A; Tonello M; Meneghel L; Robecchi B; Pittoni M; Gallo N; Salvan E; Teghil V; Punzi L; Plebani M Clin Chem Lab Med; 2014 Sep; 52(9):1329-33. PubMed ID: 24651022 [TBL] [Abstract][Full Text] [Related]
12. Anti-beta2-glycoprotein I, anti-prothrombin and anticardiolipin antibodies in a longitudinal study of patients with systemic lupus erythematosus and the antiphospholipid syndrome. Inanç M; Donohoe S; Ravirajan CT; Radway-Bright EL; Mackie I; Machin S; Isenberg DA Br J Rheumatol; 1998 Oct; 37(10):1089-94. PubMed ID: 9825748 [TBL] [Abstract][Full Text] [Related]
13. Anti-Phospholipid Antibodies in COVID-19 Are Different From Those Detectable in the Anti-Phospholipid Syndrome. Borghi MO; Beltagy A; Garrafa E; Curreli D; Cecchini G; Bodio C; Grossi C; Blengino S; Tincani A; Franceschini F; Andreoli L; Lazzaroni MG; Piantoni S; Masneri S; Crisafulli F; Brugnoni D; Muiesan ML; Salvetti M; Parati G; Torresani E; Mahler M; Heilbron F; Pregnolato F; Pengo M; Tedesco F; Pozzi N; Meroni PL Front Immunol; 2020; 11():584241. PubMed ID: 33178218 [TBL] [Abstract][Full Text] [Related]
14. Evaluation of a new set of automated chemiluminescense assays for anticardiolipin and anti-beta2-glycoprotein I antibodies in the laboratory diagnosis of the antiphospholipid syndrome. Persijn L; Decavele AS; Schouwers S; Devreese K Thromb Res; 2011 Dec; 128(6):565-9. PubMed ID: 21529896 [TBL] [Abstract][Full Text] [Related]
15. Distinguishing features of anti-beta2 glycoprotein I antibodies between patients with leprosy and the antiphospholipid syndrome. Arvieux J; Renaudineau Y; Mane I; Perraut R; Krilis SA; Youinou P Thromb Haemost; 2002 Apr; 87(4):599-605. PubMed ID: 12008941 [TBL] [Abstract][Full Text] [Related]
16. Performance of two new, automated chemiluminescence assay panels for anticardiolipin and anti-beta2-glycoprotein I antibodies in the laboratory diagnosis of the antiphospholipid syndrome. Van Hoecke F; Persijn L; Decavele AS; Devreese K Int J Lab Hematol; 2012 Dec; 34(6):630-40. PubMed ID: 22827598 [TBL] [Abstract][Full Text] [Related]
17. Evaluation of the Clinical Performance of a Novel Chemiluminescent Immunoassay for Detection of Anticardiolipin and Anti-Beta2-Glycoprotein 1 Antibodies in the Diagnosis of Antiphospholipid Syndrome. Zhang S; Wu Z; Li P; Bai Y; Zhang F; Li Y Medicine (Baltimore); 2015 Nov; 94(46):e2059. PubMed ID: 26579816 [TBL] [Abstract][Full Text] [Related]
18. Thrombotic risk assessment and analytical performance of the chemiluminescent analyzer IDS-iSYS for the detection of anti-cardiolipin and anti-beta 2 glycoprotein I autoantibodies. Salma N; Julie L; Boutahar B; Sylvie LN; Eleonore B; Fabien LN; Elisabeth P; Sandrine JJ; Francis C; Sophie H; Yves R Clin Immunol; 2018 Sep; 194():92-99. PubMed ID: 30017909 [TBL] [Abstract][Full Text] [Related]
19. Clinical characterization of antiphospholipid syndrome by detection of IgG antibodies against β2 -glycoprotein i domain 1 and domain 4/5: ratio of anti-domain 1 to anti-domain 4/5 as a useful new biomarker for antiphospholipid syndrome. Andreoli L; Chighizola CB; Nalli C; Gerosa M; Borghi MO; Pregnolato F; Grossi C; Zanola A; Allegri F; Norman GL; Mahler M; Meroni PL; Tincani A Arthritis Rheumatol; 2015 May; 67(8):2196-204. PubMed ID: 25939498 [TBL] [Abstract][Full Text] [Related]
20. A unique antiphospholipid assay recognizing phospholipid mixture compared with criteria antiphospholipid immunoassays in lupus patients. Zuo Y; Willis R; Papalardo E; Petri M; Harris EN; Schleh A; DeCeulaer K; Smikle M; Vilá LM; Reveille JD; Alarcón GS; Gonzalez EB Lupus; 2017 May; 26(6):606-615. PubMed ID: 27753626 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]